Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO phase 2 trial of olaparib maintenance versus placebo after curative-intent treatment for resected BRCA1/BRCA2/PALB2-mutated pancreatic cancer
MOH_2023-07-06_012797Phase 2Not yet recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC) comparing Olaparib with Placebo (2 arms). Planned start Jul 2023; status: not yet recruiting.
02
Drugs
olaparib
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2023-07-06_012797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-06_012797.